Sincalide

立即咨询

Sincalide

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

25126-32-3

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议

产品名称

辛卡利特
Cholecystokinin octapeptide
CCK-8
SQ19844

产品介绍

Sincalide (Cholecystokinin octapeptide, CCK‐8) 是一种速效胆囊收缩素 (CCK) 的氨基酸多肽激素类似物，在胆囊造影术中静脉使用。CCK‐8 是 CCK 的一个主要生物活性片段，它保留了 CCK 的大部分生物活性。可通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病。其增加胆汁的分泌，使胆囊收缩并使 Oddi 的括约肌松弛，从而使胆汁排入十二指肠。

生物活性

Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-actingamino acid polypeptide hormone analogueof cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK^[1]^[2]^[3].

体外研究
(In Vitro)

Sincalide (Cholecystokinin octapeptide, CCK‐8), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. CCK‐8 also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway^[3].

Cell Viability Assay^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Attenuated Ang II‐induced toxicity in H9c2 cells

Apoptosis Analysis^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Decreased apoptotic cells, and prevented Ang II‐induced cytotoxicity that involves modulation of the PI3K/Akt pathway.

Western Blot Analysis^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Expressed the protein and mRNAs of CCK and both its receptors in H9c2 cells.

RT-PCR^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Increased the protein and mRNA expression levels of CCK and decreased CCK 1 receptor expression levels at both the protein and mRNA levels with Ang II stimulation markedly.

体内研究
(In Vivo)

Sincalide (Cholecystokinin octapeptide, CCK‐8) (i.p.; 50 μg/kg/d; for 4 weeks) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model^[4].

Animal Model:	MI rat model^[4]
Dosage:	50 μg/kg
Administration:	i.p.; 50 μg/kg/d; for 4 weeks
Result:	Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.

Clinical Trial

分子量

1143.27

性状

Solid

Formula

C₄₉H₆₂N₁₀O₁₆S₃

CAS 号

25126-32-3

Sequence Shortening

D-{SO3H-Tyr}-MGWMDF-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Protect from light

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMF : 50 mg/mL(43.73 mM;Need ultrasonic)

H₂O : 0.1 mg/mL(0.09 mM;Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	0.8747 mL	4.3734 mL	8.7468 mL
5 mM	0.1749 mL	0.8747 mL	1.7494 mL
10 mM	0.0875 mL	0.4373 mL	0.8747 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： 10% DMF 90%corn oil
Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

*以上所有助溶剂都可在本网站选购。